Regional development

DGAP-News: Formycon's COVID-19 drug FYB207 Wins Prestigious Pharma Trend Image & Innovation Award 2021

Wednesday, September 15, 2021 - 8:01am

Press Release // September 15, 2021

Key Points: 
  • Press Release // September 15, 2021
    Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) yesterday received the Pharma Trend Image & Innovation "Most Innovative Product(R)" Award in the category of Leap Innovations for its COVID-19 drug development FYB207.
  • For what is now the 22nd time, the Pharma Trend Image & Innovation Awards, also known in the industry as the Pharma Oscars, were presented in various categories at a celebratory awards ceremony under the patronage of Bavarian Health Minister Klaus Holetschek, MdL.
  • "Receiving the prestigious Pharma Trend Image & Innovation 'Most Innovative Product(R)' Award for Leap Innovations is a great pleasure and encourages us in our innovative COVID-19 drug development.
  • Based on its extensive experience in the development of biopharmaceutical drugs, the company is also working on the development of an innovative COVID-19 drug.

iThera Medical leads €1.9m research project to advance optoacoustic imaging technology towards AI-supported quantitative medical diagnosis

Monday, September 13, 2021 - 1:00pm

Commenced on 1st September 2021, the project DeepOPUS (highly integrated DEtEction Platform for improved quantification and increased framerate in OPtoacoustic and UltraSound imaging) aims to further advance the established MSOT technology through use of AI.

Key Points: 
  • Commenced on 1st September 2021, the project DeepOPUS (highly integrated DEtEction Platform for improved quantification and increased framerate in OPtoacoustic and UltraSound imaging) aims to further advance the established MSOT technology through use of AI.
  • These developments will enhance diagnostic and computational performance as well as reduce the cost of the device.
  • A primary goal of the project is to increase the MSOT image quality with advanced AI methods for better usability and higher diagnostic accuracy.
  • Since its incorporation in 2010, iThera Medical develops and markets optoacoustic imaging systems for preclinical and clinical research.

Rio Tinto and Sumitomo to assess hydrogen pilot plant at Gladstone’s Yarwun alumina refinery

Tuesday, August 24, 2021 - 3:00am

Rio Tinto and Sumitomo Corporation today announced a partnership to study the construction of a hydrogen pilot plant at Rio Tintos Yarwun alumina refinery in Gladstone and explore the potential use of hydrogen at the refinery.

Key Points: 
  • Rio Tinto and Sumitomo Corporation today announced a partnership to study the construction of a hydrogen pilot plant at Rio Tintos Yarwun alumina refinery in Gladstone and explore the potential use of hydrogen at the refinery.
  • The two global companies have signed a letter of intent that focuses on Yarwun as the location for a Gladstone hydrogen plant that Sumitomo has been studying.
  • If the project proceeds, the pilot plant would produce hydrogen for the recently announced Gladstone Hydrogen Ecosystem .
  • Rio Tinto Australia Chief Executive Kellie Parker said Rio Tinto has a long relationship with Sumitomo and we are delighted to partner with them to explore the possibilities of hydrogen, not only for our own refinery, but for Sumitomo to supply industry more broadly in Gladstone.